Table 1

Updated clinical and laboratory diagnostic criteria of JMML

I. Clinical and hematologic features (all 4 features mandatory) 
 • Peripheral blood monocyte count >1 × 109/L 
 • Blast percentage in peripheral blood and bone marrow <20% 
 • Splenomegaly 
 • Absence of Philadelphia chromosome (BCR/ABL rearrangement) 
II. Oncogenetic studies (1 finding is sufficient) 
 • Somatic mutation in PTPN11* or K-RAS* or N-RAS* 
 • Clinical diagnosis of NF-1 or germline NF1 mutation 
 • Germline CBL mutation and loss of heterozygosity of CBL 
III. Only for those patients (10% of the whole number) without any oncogenetic parameter, besides the clinical and hematologic features listed under I, at least 2 of the following criteria have to be fulfilled: 
 • Monosomy 7 or any other chromosomal abnormality 
 • HbF increased for age 
 • Myeloid precursors on peripheral blood smear 
 • Spontaneous growth or GM-CSF hypersensitivity in colony assay 
 • Hyperphosphorylation of STAT5 
I. Clinical and hematologic features (all 4 features mandatory) 
 • Peripheral blood monocyte count >1 × 109/L 
 • Blast percentage in peripheral blood and bone marrow <20% 
 • Splenomegaly 
 • Absence of Philadelphia chromosome (BCR/ABL rearrangement) 
II. Oncogenetic studies (1 finding is sufficient) 
 • Somatic mutation in PTPN11* or K-RAS* or N-RAS* 
 • Clinical diagnosis of NF-1 or germline NF1 mutation 
 • Germline CBL mutation and loss of heterozygosity of CBL 
III. Only for those patients (10% of the whole number) without any oncogenetic parameter, besides the clinical and hematologic features listed under I, at least 2 of the following criteria have to be fulfilled: 
 • Monosomy 7 or any other chromosomal abnormality 
 • HbF increased for age 
 • Myeloid precursors on peripheral blood smear 
 • Spontaneous growth or GM-CSF hypersensitivity in colony assay 
 • Hyperphosphorylation of STAT5 
*

Germline mutations (indicating Noonan syndrome) need to be excluded.

Diagnosis of JMML but spontaneous regression of myeloproliferation may be noted in:

Few patients with N-RAS mutation and normal HbF.

Patients with CBL germline mutation and loss of heterozygosity.

Close Modal

or Create an Account

Close Modal
Close Modal